SCHEMBL2267331

SCHEMBL2267331

NC(CCN1CCNCC1)C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ANPEP P15144 1/20 0.44
ERAP2 Q6P179 1/20 0.44
GRM5 P41594 2/20 0.42
GRM2 Q14416 2/20 0.42
GSR P00390 2/20 0.42
GRM8 O00222 1/20 0.42
GRM6 O15303 1/20 0.42
GRIN2D O15399 1/20 0.42
GRIN3B O60391 1/20 0.42
CYP1A2 P05177 1/20 0.42
GRIK1 P39086 1/20 0.42
GRIA1 P42261 1/20 0.42
GRIA2 P42262 1/20 0.42
GRIA3 P42263 1/20 0.42
SLC1A3 P43003 1/20 0.42
SLC1A2 P43004 1/20 0.42
SLC1A1 P43005 1/20 0.42
GRIA4 P48058 1/20 0.42
GRIN1 Q05586 1/20 0.42
GRIN2A Q12879 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2267325 1.00 ANPEP (0.44) ANPEPERAP2GRM5GRM2GSR
SCHEMBL24642772 0.87 GSR (0.48) ANPEPERAP2GSRCYP1A2ALDH1A1
SCHEMBL15326764 0.86 GSR (0.50) GRM5GRM2GSRGRM8GRM6
SCHEMBL939405 0.82 CHRM5 (0.41) ANPEPERAP2GRM5GRM2GSR
SCHEMBL26912060 0.82 CHRM5 (0.41) ANPEPERAP2GRM5GRM2GSR
SCHEMBL1175906 0.82 CHRM5 (0.41) ANPEPERAP2GRM5GRM2GSR
SCHEMBL2088089 0.82 DPP7 (0.50) GRM5GRM2GSRGRM8GRM6
SCHEMBL20683320 0.82 DPP7 (0.50) GRM5GRM2GSRGRM8GRM6
SCHEMBL25662147 0.82 GSR (0.46) GRM5GRM2GSRGRM8GRM6
SCHEMBL24063106 0.82 DPP7 (0.50) GRM5GRM2GSRGRM8GRM6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8445440-B2 Dimeric IAP inhibitors NOVARTIS AG (CH) 2013-05-21 US disclosed
EP-2539333-A1 DIMERIC IAP INHIBITORS Novartis AG (CH) 2013-01-02 EP disclosed
WO-2011104266-A1 DIMERIC IAP INHIBITORS NOVARTIS AG (CH) 2011-09-01 WO disclosed
US-20110206690-A1 DIMERIC IAP INHIBITORS NOVARTIS AG (CH) 2011-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110206690-A1 DIMERIC IAP INHIBITORS XIAP, BIRC5, BIRC2 ANPEP 457/4885ERAP2 891/4885GRM5 3944/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.